Sep. 1, 2020
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
A Report of the American College of Cardiology Solution Set Oversight Committee.
Sandeep R Das, Brendan M Everett, Kim K Birtcher et al. - Journal of the American College of Cardiology
The 2020 ACC Expert Consensus updated the decision pathway for SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes, integrating evidence from DAPA-HF, CREDENCE, and other contemporary trials to guide agent selection based on predominant cardiovascular or renal comorbidity.
